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Treatment with Lipopolysaccharide (LPS): Macrophage cell cultures (Raw 264.7 cells), were 
seeded on multiple 12-well plates. After an initial incubation period, the cells were treated for 18 
hours with 1 or 10 ng/ml of LPS. To observe the level of NE release, the LPS-treated Raw 264.7 
cells in conditioned media were analyzed by ELISA. To quantify the level of M1 and M2 
macrophage phenotype expression, mRNA was extracted and quantitative real-time PCR was 
performed for M1 and M2 phenotype markers (iNOS, IL-6, IL-1β and TNF-α for M1 and IL-10, 
Arginase-1, and TGF- β for M2). 
      
Treatment with Norepinephrine (NE): Raw 264.7 cells, consisting of macrophage cell cultures, 
were obtained and seeded on multiple 12-well plates. After an initial incubation period, the cells 
were treated for 18 hours with 1, 10, or 50 µM of NE. To observe the level of M1 and M2 
macrophage phenotype expression, quantitative real-time PCR was performed. Certain M1 and 
M2 phenotype markers were measured in the mRNA that was extracted (iNOS, IL-6, IL-1β and 
TNF-α for M1 and IL-10, Arginase-1, and TGF- β for M2). Slides of the Raw 264.7 cells were 
stained with M1 and M2 phenotypic markers (IL-1β for M1 and TGF-β for M2) to highlight the 
differences between representative images of the control samples and the Raw 264.7 cells treated 
with 10 µM of NE.     
Preparation of Slides: Raw 264.7 cells were cultured on coverslips and treated for 18 hours with 
10 µM of NE. They were subsequently stained with M1 or M2 phenotypic markers (IL-1β for M1 
and TGF-β for M2). Representative images of the control samples and the Raw 264.7 cells were 
then photographed with the microscope. 
Treatment of Raw 264.7 Cells with LPS Activates Expression of 
M1 and M2 Macrophage Phenotypes
Acknowledgments
Treatment of Raw 264.7 Cells with LPS Induces Norepinephrine 
Release
Treatment of Raw 264.7 Cells with NE Also Activates Expression of M1 and M2 Macrophage 
Phenotypes
Conclusions and Future Implications
The results show that LPS, which is used to replicate renal ischemia reperfusion injury, influences both M1 and M2 
macrophage phenotype expression in raw cells and induces NE release. The results also show that, like LPS, 
treatment with NE also influences both M1 and M2 macrophage phenotype expression in raw cells. This suggests that 
NE may act as an activator for the M1 and M2 macrophage phenotypes after ischemic injury to the renal system, 
leading to the renal fibrogenesis and inflammation usually seen in chronic kidney disease. Therefore, the inhibition of 
NE release may represent a novel and effective therapeutic strategy that can be used to prevent renal fibrogenesis and 




Renal denervation before ischemic injury has been shown to protect against fibrogenesis and the 
inflammatory response, which are two causes for the progression of chronic kidney disease. 
However, the administration of norepinephrine (NE) to denervated renal systems induced 
fibrogenesis and inflammation after ischemic injury. Our previous data indicates that NE-mediated 
stimulation of the α2-AR receptors is responsible for regulating several of the processes implicated 
in fibrogenesis and inflammation, including the accumulation, migration, and infiltration of 
macrophages to the site of injury; this is especially relevant as macrophages have been implicated as 
one potential cause for the inflammatory response. 
       
Recent studies, completed in response to the idea that stimulation with clonidine or moxonidine 
seems to protect against renal fibrogenesis, suggest that NE-mediated stimulation of the α2-AR 
receptors is responsible for fibrogenesis and inflammation. This is supported by the fact that 
moxonidine inhibits the release of norepinephrine while simultaneously stimulating the central α2-
AR receptors while clonidine is responsible for preventing the release of renin which, as explained 
by the renin- angiotensin-aldosterone system, prevents the release of norepinephrine from 
sympathetic nerve endings and the inhibition of its re-uptake. However, there are few studies that 
explain how the absence of norepinephrine could affect macrophage function. 
       
To define the role that norepinephrine plays in renal fibrogenesis and the inflammatory response 
after ischemia, three experiments were performed to answer the following questions: 1. Can treating 
the macrophage cell cultures with LPS induce differentiation between M1 and M2 macrophage 
phenotypes? 2. Do injured macrophages have the capacity to release norepinephrine? and 3.If so, 
what is the effect of varying concentrations of norepinephrine on the differentiation between M1 and 
M2 macrophage phenotypes?
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Figure 3. Effect of lipopolysaccharide on norepinephrine release. Raw 264.7 cells were 
treated for 18 h with 1 or 10 ng/ml of lipopolysaccharide. The level of norepinephrine in LPS-
treated Raw 264.7 cells conditioned media was analyzed using ELISA. Results are expressed as 
the mean ± SE (n=3). *, p<0.5; **, p<0.01. LPS, lipopolysaccharide. 
Figure 2. Effect of lipopolysaccharide on the M2 macrophage phenotype. Raw 264.7 cells were 
treated for 18 h with 1, or 10 ng/ml of lipopolysaccharide. (A-C) The levels of IL-10, Arginase-1, and 
TGF- β mRNA were determined by quantitative real-time PCR. Expression of all genes is normalized to 
GAPDH. Results are expressed as the mean ± SE (n=3). *, p<0.5; **, p<0.01. LPS, lipopolysaccharide. 
Figure 1. Effect of lipopolysaccharide on the M1 macrophage phenotype. Raw 264.7 cells were 
treated for 18 h with 1, or 10 ng/ml of lipopolysaccharide. (A-D) The levels of iNOS, IL-6, IL-1β and 
TNF-α mRNA were determined by quantitative real-time PCR. Expression of all genes is normalized to 
GAPDH. Results are expressed as the mean ± SE (n=3). *, p<0.5; **, p<0.01. LPS, lipopolysaccharide.
Figure 4. Effect of norepinephrine on the M1 macrophage phenotype. Raw 264.7 cells were treated for 18 h with 1, 10, or 50 
µM of norepinephrine. (A-D) The levels of iNOS, IL-6, IL-1β and TNF-α mRNA were determined by quantitative real-time PCR. 
Expression of all genes is normalized to GAPDH. (E) Representative images of IL-1β in control or 10 µM of norepinephrine 
treated-Raw 264.7 cell. Results are expressed as the mean ± SE (n=3). *, p<0.5; **, p<0.01. NE, norepinephrine. Scale bar=10 µm. 
Figure 5. Effect of norepinephrine on the M2 macrophage phenotype. Raw 264.7 cells were treated for 18 h with 1, 10, or 50 
µM of norepinephrine. (A-C) The levels of IL-10, Arginase-1, and TGF- β mRNA were determined by quantitative real-time PCR. 
Expression of all genes is normalized to GAPDH. (D) Representative images of TGF-β in control or 10 µM of norepinephrine 
treated-Raw 264.7 cell. Results are expressed as the mean ± SE (n=3). *, p<0.5; **, p<0.01. NE, norepinephrine. Scale bar=10 µm.
The treatment of Raw 264.7 with LPS cells induces M1 macrophage activation.
The treatment of Raw 264.7 with LPS cells induces M2 macrophage activation.
The treatment of Raw 264.7 with NE induces M1 macrophage activation.
The treatment of Raw 264.7 with NE induces M2 macrophage activation.
